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ABSTRACT
Objective: To determine the genetic cause of slowly progressive cerebellar ataxia, sensorineural
deafness, and hypergonadotropic hypogonadism in 5 patients from 3 different families.
Methods: The patients comprised 2 sib pairs and 1 sporadic patient. Clinical assessment included
history, physical examination, and brain MRI. Linkage analysis was performed separately on the 2
sets of sib pairs using single nucleotide polymorphism microarrays, followed by analysis of the
intersection of the regions. Exome sequencing was performed on 1 affected patient with variant
filtering and prioritization undertaken using these intersected regions.
Results: Using a combination of sequencing technologies, we identified compound heterozygous
mutations in HSD17B4 in all 5 affected patients. In all 3 families, peroxisomal D-bifunctional
protein (DBP) deficiency was caused by compound heterozygosity for 1 nonsense/deletion muta-
tion and 1 missense mutation.
Conclusions: We describe 5 patients with juvenile DBP deficiency from 3 different families, bring-
ing the total number of reported patients to 14, from 8 families. This report broadens and consol-
idates the phenotype associated with juvenile DBP deficiency. Neurol Genet 2016;2:e114; doi:
10.1212/NXG.0000000000000114
GLOSSARY
CoA 5 coenzyme A; DBP 5 D-bifunctional protein; FSH 5 follicle-stimulating hormone; LH 5 luteinizing hormone; MPS 5
massively parallel sequencing; SNP 5 single nucleotide polymorphism; VLCFA 5 very long-chain fatty acid.
Peroxisomal D-bifunctional protein (DBP) deficiency is an autosomal recessive disorder that
compromises peroxisomal fatty acid oxidation. DBP is crucial to the b-oxidation of fatty acids
in the peroxisome, catalyzing the second and third steps of this process which are performed,
respectively, by a 2-enoyl-coenzyme A (CoA) hydratase unit and a 3-hydroxyacyl-CoA dehy-
drogenase unit.1 DBP deficiency is typically associated with a severe clinical presentation com-
prising neonatal hypotonia, seizures, and severely impaired psychomotor development.1
Dysmorphism, loss of hearing and vision, and CNS abnormalities also commonly occur.
Infant onset DBP deficiency has been classified into 3 subgroups based on the relative impair-
ment of the 2 DBP functions.2 Type I deficiency represents a total deficiency of both the
hydratase and hydroxyacyl-CoA dehydrogenase activities. Type II is an isolated deficiency of
the hydratase activity, and type III is an isolated deficiency of the hydroxyacyl-CoA dehydro-
genase activity. The 3 subgroups share a similar spectrum of clinical features but differ in
severity: nearly all infants with type I deficiency die in the first year of life, whereas those with
types II and III often survive beyond 10 years.1
Recently, a less severe form of DBP has been described in 5 families3–7 and designated
juvenile DBP deficiency,5 or alternatively DBP deficiency type IV6 or multifunctional protein
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ataxia syndrome.8 Here, we describe 5 affected
individuals from 3 new families affected by
juvenile DBP deficiency and expand the pub-
lished phenotypic spectrum for this disorder.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the Royal
Children’s Hospital Human Research Ethics Committee
(approval number 28097). Participants were recruited following
review of clinical details obtained frommedical records and family
interviews. Each participant signed an informed consent docu-
ment before enrollment.
Genetic analysis. Genetic studies were performed essentially as
described previously.9 Genomic DNA isolated from the periph-
eral blood and single nucleotide polymorphism (SNP) genotype
data were generated. Parametric multipoint linkage analysis was
performed specifying a rare recessive disease model. Genomic
DNA was analyzed by whole-exome capture (Illumina TruSeq
capture kit, San Diego, CA), and massively parallel sequencing
(MPS) was performed on a HiSeq2000 (Axeq Technologies,
Macrogen, Seoul, Korea). Reads were aligned to the reference
genome with Novoalign, and variants were identified with
SAMtools and annotated by ANNOVAR. Variants were
filtered in a step-wise manner against exclusion criteria
including linkage region, minor allele frequency (#0.01,
1000 Genomes10), and functional impact. Inclusion criteria
included predicted damaging effects on the protein using
PolyPhen-2 and SIFT. Sanger sequence analysis of HSD17B4
was performed by PCR amplification (primer sequences
available on request). Primary fibroblast cells were analyzed by
Western blot as previously described11 using anti-HSD17B4
(1:1000 HPA021479; Sigma-Aldrich, St. Louis, MO) and
anti–b-actin antibody (1:10000 A5441; Sigma-Aldrich). The
reference sequences used for HSD17B4 were NG_008182.1,
NM_000414.3, and NP_000405.1.
RESULTS Clinical descriptions. The clinical details of
5 affected individuals from 3 pedigrees are presented
in table 1 and the family pedigrees in figure 1A.
Pedigree 1, comprising 2 affected sisters of
Italian descent (II-1 and II-2), was published previ-
ously under the designation “Cerebellar ataxia with
hypergonadotropic hypogonadism” (OMIM
#605672),12 prior to the identification of
HSD17B4 mutations. Briefly, the sisters, aged 57
and 63 years at the most recent follow-up, both
presented with adult-onset progressive cerebellar
ataxia and secondary amenorrhea due to hypergo-
nadotropic hypogonadism. Intellect was normal,
peripheral sensory neuropathy was observed, and
there was sensorineural deafness with vestibular hy-
pofunction. Neurologic symptoms were observed in
the third decade, and secondary amenorrhea was
described at 16 and 32 years of age, respectively.
Brain MRI on both sisters showed marked atrophy
of the cerebellum, involving both hemispheres and
vermis. Additional metabolic studies were under-
taken in the younger sister (II-2). Plasma levels of
very long-chain fatty acids (VLCFAs) were normal:
C24:0/C22:0 ratio was 0.762 (reference 0.550–
1.115) and C26:0/C22:0 ratio was 0.020 (reference
,0.035). Plasma phytanic acid level was 0.1 mg/
100 mL (reference ,0.7). Urine bile acid profile
was normal.
Pedigree 2 includes 2 affected siblings, a male
and a female, along with 3 unaffected female sib-
lings born to nonconsanguineous parents of Leba-
nese descent. The male sib (II-2) presented at age
29 years with a 5-year history of progressive ataxia.
His workmates had noticed impaired balance and
slurred speech, of which he was unaware. Increased
falls and deteriorating handwriting had been noted
for 3 years. He had not noted any visual or hearing
impairment or sensory symptoms, and there was no
erectile dysfunction.
Examination revealed a very broad-based ataxic
gait with mild cerebellar dysarthria. There was bilat-
eral horizontal gaze-evoked nystagmus, but horizontal
saccades appeared normal. Upward saccades were hy-
pometric, and downward saccades hypermetric. Tone
and power were normal in the limbs, and deep ten-
don reflexes were reduced but present without
enhancement. There was bilateral appendicular
ataxia, with notably slow and hypermetric ballistic
tracking (“finger chase”) movements. Vibration and
pinprick perception were intact distally, but 2-point
discrimination was clearly impaired at the great toes
(2.5 cm). Brain MRI at age 25 years showed mild
cerebellar atrophy with vermal emphasis and normal
brainstem and cerebrum. Audiology showed moder-
ate high-frequency hearing loss. At follow-up assess-
ment 1 year later, his testosterone, luteinizing
hormone (LH), follicle-stimulating hormone (FSH),
and sperm count were normal. He had naturally con-
ceived 2 sons and a daughter. Five years later, he
required a wheelchair for mobility outside the house.
His vibration perception threshold was well below the
fifth percentile for his age, but pinprick sensation
remained intact.
The sister of the family proband (II-1) presented
at age 31 years with a 4-year history of dysarthria
and impaired balance, although she reported always
sensing some imbalance. She had been referred to
an ENT specialist, who had discovered moderate
high-frequency sensorineural hearing loss (figure
2A). Ovarian failure had been diagnosed on investi-
gation for primary amenorrhea. Examination revealed
a mildly broad-based gait and mild cerebellar dysar-
thria. Visual smooth pursuit was normal, and imper-
sistent horizontal gaze-evoked nystagmus was evident
on right gaze (only). Saccades to target were hyper-
metric to the right and into down gaze. Tone, power,
and reflexes were normal in the limbs. There was mild
appendicular ataxia. Vibration and pinprick percep-
tion and 2-point discrimination were normal at the
2 Neurology: Genetics
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Table 1 Summary of clinical details of affected individuals in this study and previously reported in the literature










MK LK 1 2 1 2 3 II-1 II-2 II-1 II-2 II-1
Sex, age at the last report, y F, 27 F, 16 M, 16 M, 14 M, 35 F, 39 M, 38 F, 35 F, 43 F, 64 F, 55 F, 41 M, 40 M, 33
Age at chief symptom onset, y
Hearing loss 1 (8) 1 (4) 1 (3.5) 1 (2) 1 (34) 1 (5) 1 (8) 1 (10) 1 1 (,20) 1 (20) 1 (27) 1 (30) 1 (6)
Ataxia 1 (5–10) 2 1 (11) 2 1 (,18) 1 (12) 1 (10) 1 (14) NR 1 (20) 1 (20) 1 (20) 1 (24) 1 (12)
Cognition LD NR None None LD LD ID ID ID None None None None None
Cerebellum
Dysarthria 1 2 NR NR 1 1 1 1 NR 1 1 1 1 1
Nystagmus 1 NR NR NR 1 1 1 1 NR 1 1 1 1 1
Mobility aids (age required, y) WC (,23) None WC None WC (29) Walker WC (32) None NR Walker (60) None None WC (35) None
Motor
Weakness 1 1 1 NR NR 1 2 1 NR 2 2 2 2 2
Lower extremity spasticity 1 2 NR NR NR 1 1 1 NR 2 2 2 2 2
Hyperkinesia NR NR NR NR NR 1 2 1 NR 1 2 2 2 2
Deep tendon reflexes Present Present Y NR [ Y [ Y NR Y Y Present Y Present
Plantar responses NR NR Flexor NR Flexor Extensor Extensor Flexor NR Flexor Flexor Flexor Flexor Flexor
Sensory
Pinprick Y Normal Y NR Y Y NR Normal NR Normal Y Normal Normal Normal
Vibration Y Y Normal NR NR Y Y Y NR Y Y Normal Y Normal
Cranial MRI, y
Cerebellar atrophy 1 (21) 2 (,16) 1 (12) 1 1 (14) 1 (21) 1 (25) 1 (24) NR 1 (45) 1 (39) 1 (30) 1 (25) 1 (25)
White matter lesions 2 (23) 2 (,16) 2 (12) 2 2 (35) 1 (39) 1 (25) 2 (24) NR 2 2 2 (30) 2 2
Endocrine
Amenorrhea 1° 1° NA NA NA 1° NA 2° 1° 2° 2° 1° NA NA
Testosterone level NR NA NR NR Y NA Y NA NA NA NA NA Normal Normal
Azoospermia NA NA NR NR 1 NA NR NA NA NA NA NA 2 1




































great toes. Brain MRI performed at age 31 years
showed clear pancerebellar atrophy, with normal
brainstem and cerebrum (figure 2B). At age 37 years,
she reported tinnitus, mild dysphagia, and worsening
dysarthria and ataxia. There was evidence of sensory
neuropathy with reduced vibration perception and 2-
point discrimination at the great toes, although
pinprick perception was preserved and ankle jerks
were present.
Pedigree 3 includes 1 affected individual (II-1),
a 33-year-old man born to nonconsanguineous pa-
rents of Italian ancestry. His younger brother is unaf-
fected. He presented at age 6 years with bilateral
sensorineural hearing loss, for which he has used hear-
ing aids from age 7 years. Beginning at age 14 years,
he developed a very slowly progressive cerebellar
ataxia. A decline in gait was first noted in the early
teenage years, with incoordination and occasional
falls becoming gradually more evident. There have
not been any problems with vision, or with motor
weakness or sensory disturbance. He has never had
a tremor or involuntary movements, and there is no
history of myoclonus or seizures. His cognitive devel-
opment is entirely normal. Clinical examination re-
vealed gait ataxia, dysarthria, and limb ataxia,
consistent with cerebellar disease. Although his ocular
movements have a full range, visual pursuit was sac-
cadic, with saccades being hypermetric in the hori-
zontal plane, and there was marked gaze-evoked
nystagmus, particularly on left gaze. Tongue move-
ments were slightly slow. There was no evidence of
motor weakness or sensory loss. Serial brain MRI
demonstrated progressive pancerebellar atrophy with
normal brainstem appearance. Nerve conduction
studies did not show evidence of peripheral neuropa-
thy. He was infertile due to hypergonadotropic hypo-
gonadism with elevated FSH (33.8 IU/L N 1.5–12.4)
and normal LH (7.6 IU/L N 1.7–8.6). Serum testos-
terone was at the lower end of the normal range (9.6
nmol/L N 8.3–30.2). A semen analysis showed azo-
ospermia, and a testicular biopsy revealed no sperm
and germ cell arrest. Serum phytanic acid was normal.
Mutation identification and characterization. DNA
from the 2 siblings from pedigree 1 and their
mother were hybridized to Affymetrix Genome-
wide 6.0 SNP chips. From the genotyping data,
we identified regions where the affected siblings
were sharing both maternal and paternal
haplotypes (IBD2 regions), thereby eliminating
candidate genes over 3 quarters of the genome. In
addition, no copy number variants of interest
were detected in this family.
DNA from the 2 affected siblings from pedigree 2
was hybridized to Illumina Human 610-quad bead-
chips. From the genotyping data, we identified
IBD2 regions between the siblings which covered
approximately 30% of the autosome, with 40 separate
intervals. The male sib then underwent MPS, and
variant filtering was restricted to these linkage regions.
As the suspected disease model was compound het-
erozygous, the filtering process only included genes
that had 2 potential causative mutations. This
Figure 1 Compound heterozygous mutations in HSD17B4 cause juvenile
peroxisomal D-bifunctional protein deficiency
(A) Pedigree structure of families with cerebellar ataxia with hypergonadotropic hypogonad-
ism. Affected individuals are represented by black symbols. DNA from individuals that was
used in this study is indicated (*). Single nucleotide polymorphism arrays and linkage were
performed on samples I-2, II-1, II-2 (family 1), and II-1 and II-2 (family 2); WES was performed
on sample II-2 (family 2). (B) A schematic representation of HSD17B4 indicating the dehy-
drogenase, hydratase, and SCP2 domains. The position and type of all compound heterozy-
gous mutations identified in the 8 families reported with juvenile peroxisomal D-bifunctional
protein deficiency to date (table 2) are indicated. A5 pedigree 1, B5 pedigree 2, C5 pedigree
3, andD–Hcorrespond to families 4–8, respectively. (C) Immunoblot analysis with an HSD17B4-
specific antibody (1:1000, HPA021479) identified a ;80 kDa full length and ;35 kDA pro-
cessed dehydrogenase domain protein in control fibroblasts (C1 and C2) that was significantly
reduced in extracts derived from affected individuals II-1 and II-2 (families 1 and2). An antibody
directed against b-actin confirmed equivalent protein loading. FB 5 fibroblast. FB5 fibroblast.
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filtering resulted in 20 candidate genes containing 40
potential causative mutations.
Linkage regions from pedigrees 1 and 2 were then
intersected, and subsequent variant filtering and pri-
oritization was undertaken using these regions. This
analysis identified HSD17B4 as a promising candi-
date, with 2 mutations identified in the male sib.
The first variant (NM_000414(HSD17B4_v003):
c.661C.T, p.(Leu221Phe) is a missense mutation,
absent in population databases, that is predicted to be
possibly damaging/deleterious by PolyPhen-2 and
SIFT, respectively. The second variant (c.1132
G.T, p.Gly378*) is a nonsense mutation, most
likely resulting in nonsense-mediated decay or a trun-
cated protein product. The 2 variants were confirmed
by Sanger sequencing in both siblings, and each par-
ent was found to carry one of the variants, consistent
with a compound heterozygous disease model.
Sanger sequencing was then undertaken in the 2
sisters from pedigree 1 and their unaffected mother.
The same 2 variants were identified in both affected
sisters. The first variant (c.5811 G.A) is predicted
to cause loss of the exon 1 donor splice site. The
second variant (c.293A.AG, p.Asn98Ser) is a mis-
sense mutation predicted to be damaging/deleterious.
The mother of the sisters was sequenced and found to
have the c.293A.AG, p.Asn98Ser variant but not
the c.5811 G.GA variant. The father was not avail-
able for the study.
Sanger sequencing of HSD17B4 was then per-
formed in pedigree 3. Two variants were identified
in the affected male. The first variant in exon 4
(c.186_187del:pIle62Metfs*12) is a 2-base pair dele-
tion (AA) causing a frameshift and a premature stop
codon. The second variant is a missense mutation
(c.680A.G;p.His227Arg) that is predicted to be
probably damaging/deleterious. Each variant was
present in one unaffected parent, consistent with
a compound heterozygous disease model. Only one
of the 2 mutations (c.680A.G;p.His227Arg) was
present in his unaffected brother.
To determine the functional effect of mutations in
HSD17B4, Western blot analysis of primary fibro-
blasts derived from all affected members in families
1 and 2 was performed. The 736 amino acid, 79.6
kDa protein encoded by HSD17B4 includes con-
served dehydrogenase, hydratase, and SCP2 domains
(figure 1B). In control fibroblast cells, an intense
band of the expected size (approximately 80 kDa)
was detected using an anti-HSD17B4 antibody. In
addition, a band consistent with the ;35 kDA pro-
cessed dehydrogenase domain13 was also observed.
The relative abundance of both of these proteins
was significantly reduced in patient fibroblasts from
families 1 and 2 (figure 1B).
DISCUSSION The reported phenotype of juvenile
DBP deficiency is characterized by childhood or early
adult-onset sensorineural deafness, ataxia, and
hypergonadotropic hypogonadism and overlaps
with that of Perrault syndrome (sensorineural
deafness and, in females, ovarian dysgenesis).3–7
Here, we describe 5 patients with juvenile (type
IV) DBP deficiency from 3 different families,
bringing the total number of reported patients to
14, from 8 families. We previously classified the
family reported here as pedigree 1 as being affected
by “Cerebellar ataxia with hypergonadotropic
hypogonadism” (OMIM #605672)12; however, it is
now clear that this is the same disorder as juvenile
DBP deficiency.
This report broadens and consolidates the pheno-
type associated with juvenile DBP deficiency. The 3
cardinal manifestations of juvenile DBP deficiency
are ataxia associated with cerebellar atrophy on
MRI, sensorineural deafness, and hypergonadotropic
hypogonadism. The disorder is slowly progressive
with the onset of hearing loss and ataxia typically in
the first decade of life; however, symptoms may
escape recognition until the second or even the third
decade. Peripheral neuropathy, affecting large diame-
ter sensory fibers clinically, typically develops some
years after the onset of deafness and ataxia. Ambula-
tion is progressively impaired, with some patients
requiring the use of a wheelchair between the third
and sixth decades. Notably, our oldest patient was
ambulant with a walker in her 60s.
Gonadal dysfunction in juvenile DBP deficiency
shows greater variability. Of the 8 females identified
with this disorder, 5 have had primary ovarian insuf-
ficiency, whereas 3 have undergone spontaneous
Figure 2 Loss of HSD17B4 results in sensorineural deafness and slowly
progressive cerebellar ataxia
(A) Audiogram from patient II-2, pedigree 2 showing high-frequency sensorineural hearing
loss. (B) Brain MRI from the same patient showing marked cerebellar atrophy. PTA 5 pure-
tone audiometry.
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puberty, followed some years later by premature men-
opause; none has had children. Of the 6 males with
juvenile DBP deficiency, information about gonadal
function is available for only 4. From previous re-
ports, 2 males have been described as having low tes-
tosterone levels,4,5 of whom 1 had a semen analysis
showing azoospermia.4 We report similar findings in
one of our affected males (pedigree 3, II:1) who had
a testosterone level at the lower end of the normal
range associated with an elevated FSH level, and a tes-
ticular biopsy that showed germ cell arrest. In con-
trast, our other affected male had normal testicular
function and fathered 3 children. Our data suggest
that infertility is not a certain outcome for male in-
dividuals with DBP deficiency.
Juvenile DBP deficiency shares some features with
the severe neonatal forms of DBP deficiency, notably
the presence of hearing loss, cerebellar atrophy, and
peripheral neuropathy; however, a number of features
of neonatal onset DBP deficiency are absent from
juvenile DBP deficiency, including hypotonia, seiz-
ures, visual loss, liver disease, and cortical malforma-
tions.1 Notably, all 5 of our patients had normal
intelligence, although learning difficulties and intel-
lectual disability have been described in other pa-
tients. The 3 siblings previously reported5 differ
somewhat from the other juvenile DBP patients with
respect to the presence of intellectual disability (rang-
ing from mild to severe), spasticity, and white matter
changes on MRI; these findings may be specific to the
combination of mutations in these siblings.
It is important that the routine peroxisomal
screening tests (VLCFA and phytanic acid levels),
which are helpful in diagnosing the infantile forms
of DBP deficiency, have, when tested, been consis-
tently normal in juvenile DBP deficiency,3,5,7 includ-
ing both of our patients who were tested. In the
absence of a biochemical screening test, diagnosis of
juvenile DBP deficiency relies on the recognition of
the characteristic clinical presentation. It is therefore
likely that juvenile DBP deficiency is an underdiag-
nosed entity and that further cases will come to light
with the increased use of exome sequencing.
In common with other disorders of peroxisomal
function, in DBP deficiency, our understanding of
the links between cellular mechanisms and disease
pathogenesis is incomplete. For some reason, the cer-
ebellum is exquisitely sensitive to perturbations in
peroxisomal function and cerebellar pathologies,
including hypoplasia, atrophy, and demyelination,
are common features of peroxisomal disorders.8 It is
possible that neurodegeneration results from a combi-
nation of both the accumulation of toxic peroxisomal
metabolic substrates (e.g., VLCFAs and phytanic
acid) and deficiency of peroxisomal synthetic prod-
ucts; however, studies in knockout mice have failed to
correlate neurodegeneration with the level of any can-
didate metabolite.8 It has been hypothesized that per-
oxisome dysfunction leads to widespread molecular
and metabolic changes within the cell, including
altered cell signaling, increased oxidative stress, and
impaired mitochondrial function, and that these in
turn lead to altered neuronal function and neuronal
cell death.14
There is a correlation between DBP subgroups
and genotype, with type I deficiency associated with
nonsense and deletion mutations, type II deficiency
associated with missense mutations in the hydratase
unit, and type III deficiency associated with missense
mutations in the hydroxyacyl-CoA dehydrogenase
unit.13 Analysis of the genotypes of the 8 families with
juvenile DBP deficiency (table 2) demonstrates that
all affected individuals are compound heterozygotes,
either for 2 missense mutations or for 1 missense
mutation and 1 nonsense/deletion mutation. Of
interest, 5 of the 8 families, including the 3 families
reported here, are compound heterozygous for 1 non-
sense/deletion mutation (the latter typically associ-
ated with type I DBP deficiency) and 1 missense
mutation in the hydroxyacyl-CoA dehydrogenase
unit, making this the most common genotypic cate-
gory for juvenile DBP deficiency. Of the other fam-
ilies, one is compound heterozygote for 2 missense
mutations in the hydroxyacyl-CoA dehydrogenase
unit and another is compound heterozygous for 2
missense mutations in the hydratase unit. Although
it was previously suggested that juvenile DBP defi-
ciency might be specifically associated with the pres-
ence of 1 mutation in each of the hydratase and
hydroxyacyl-CoA dehydrogenase units,6 only 1 fam-
ily has been described with this combination of muta-
tion types. Notably, 3 of the mutations reported in
juvenile DBP deficiency have previously been re-
ported in patients with neonatal DBP deficiency,
Table 2 Summary of genotypes observed in affected individuals in this study
and previously reported in the literature
Family Mutation 1 Mutation type Mutation 2 Mutation type
Pierce et al.7 p.Tyr568* I p.Tyr217Cys III
McMillan et al.6 p.Ala34Vala III p.Ile516Thra II
Lieber et al.4 p.239_403del I p.Ala196Val III
Lines et al.5 p.Pro513Thr II p.Arg543Pro II
Demain et al.3 p.Gly16Sera III p.Val82Phe III
Pedigree 1 c.5811 G.GA I p.Asn98Ser III
Pedigree 2 p.Gly378* I p.Leu221Phe III
Pedigree 3 p.Ile62Metfs*12 I p.His227Arg III
Mutation types: I 5 deletion/nonsense mutation; II 5 missense mutation in hydratase unit;
III 5 missense mutation in hydroxyacyl-CoA dehydrogenase unit.
a Previously reported in patients with neonatal presentation.
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indicating genotypic overlap between the subtypes of
DBP deficiency.
Juvenile DBP deficiency shares phenotypic fea-
tures with Perrault syndrome and has been described
by some authors as a type of Perrault syndrome.3,7
Perrault syndrome is an autosomal recessive syn-
drome, the cardinal features of which are sensorineu-
ral hearing loss in both sexes and primary ovarian
insufficiency in females. Additional neurologic fea-
tures such as ataxia, neuropathy, and intellectual dis-
ability are present in some patients, but are not
required for diagnosis. Apart from HSD17B4, the
other 4 genes so far associated with Perrault syndrome
all encode mitochondrial proteins.3 Although there is
obvious clinical overlap between juvenile DBP defi-
ciency and Perrault syndrome, we believe that the
conditions are sufficiently clinically and molecularly
distinct for juvenile DBP deficiency not to be classi-
fied as a subtype of Perrault syndrome.
AUTHOR CONTRIBUTIONS
D.J.A. formulated the study, performed patient recruitment, provided
and interpreted the clinical data, and cowrote the manuscript. A.P.L.
M. performed molecular analysis and revised the manuscript. E.S. con-
tributed to the design of the study, provided and interpreted the clinical
data, and revised the manuscript. R.T. performed bioinformatic analysis,
interpreted the data, and revised the manuscript. G.G. performed molec-
ular analysis and revised the manuscript. M.B.D. contributed to the
design of the study, provided and interpreted the clinical data, and revised
the manuscript. K.P. performed patient recruitment, collected clinical
data, and revised the manuscript. C.B. performed bioinformatic analysis,
interpreted the data, and revised the manuscript. R.J.L. contributed to
the design of the study, provided and interpreted the clinical data, and
revised the manuscript. M.B. contributed to the design of the study, per-
formed bioinformatic analysis, interpreted the data, and revised the man-
uscript. P.J.L. formulated the study, interpreted the data, and cowrote the
manuscript.
ACKNOWLEDGMENT
The authors thank the families involved in this research and acknowledge
the generous support of the Lefroy and Handbury families.
STUDY FUNDING
This work was funded in part by National Health and Medical
Research Council Australia Program Grant 490037 to D.J.A. and
M.B. A.P.L.M. and R.T. are supported by APA scholarships funded
by the Australian Government. M.B. is supported by an ARC
Future Fellowship (FT100100764), and P.J.L. is supported by an
NHMRC Career Development Fellowship (APP1032364). R.J.L.
is supported by a Melbourne Children’s Clinician-Scientist Fellow-
ship. This work was made possible through the Victorian State
Government Operational Infrastructure Support and Australian
Government NHMRC IRIISS.
DISCLOSURE
Dr. Amor has received research support from Cancer Council Australia,
NHMRC, and Cancer Australia & Prostate Cancer Foundation of
Australia. Ms. Marsh reports no disclosures. Dr. Storey has served on
the scientific advisory board of the Bethlehem-Griffiths Foundation
(received payment in kind); has served on the editorial board of Cerebel-
lum and Ataxias; and has received research support from the National
Health and Medical Research Council of Australia and NIH. Mr.
Tankard has received research support from the Australian Postgraduate
Award scholarship. Ms. Gillies has received research support from
NHMRC. Dr. Delatycki has served on the editorial boards of BMC
Neurology and the Journal of Pediatric Genetics and has received research
support from NHMRC, FARA USA, and FARA Australia. Ms. Pope has
received research support from NHMRC. Ms. Bromhead reports no
disclosures. Dr. Leventer has received research support from NHMRC
and the Campbell Edwards Trust. Dr. Bahlo has served on the scientific
advisory boards of the Macular Telangiectasia (MacTel) Consortium and
the Department of Health (Australian Government); has received travel
funding/speaker honoraria for the 7th International Conference on Ge-
nomics & Bio-IT APAC 2012, the International Mathematics Institute
conference (Pacific Region), the Australian Statistical Society Conference,
the International Stroke Genetics Meeting, the Human Genome Meet-
ing, AGTA, and the MacTel Consortium Meeting; has served on the
editorial board of Statistical Applications in Genetics and Molecular Biology;
holds a patent for Method of determining response to treatment with
immunomodulatory composition Details genetic markers that predict
response to Hepatitis C treatment; has been a consultant for the MacTel
Consortium, the Human Genetics Society of Australia, the Australian
Statistical Society-Institute of Mathematical Statistics, the International
Conference on Systems Biology, the Sixth Barossa Meeting, and the 8th
International Conference on Genomics & Bio-IT APAC; and has
received research support from NHMRC, the Australian Research Coun-
cil (ARC), the Victorian Life Sciences Computing Initiative (VLSCI), the
Royal Melbourne Hospital Home Lottery Research Awards, the Leuke-
mia Foundation National Research Program, the ARC Future Fellow-
ship, ARC Linkage Grant, DEST International Science Linkages grant,
the Human Genetics Society of Australia, the Epilepsy Society of
Australia, the Royal Statistical Society, the Institute of Mathematical
Statistics, the Biometrics Society of Australasia, the Australian Statistics
Society, the American Society of Human Genetics, and the International
Genetic Epidemiology Society. Dr. Lockhart has served on the editorial
boards of Genetics Research International and Open Access (OA) Genetics
and has received research support from NHMRC. Go to Neurology.org/
ng for full disclosures.
Received July 24, 2016. Accepted in final form September 6, 2016.
REFERENCES
1. Ferdinandusse S, Denis S, Mooyer PA, et al. Clinical and
biochemical spectrum of D-bifunctional protein defi-
ciency. Ann Neurol 2006;59:92–104.
2. Wanders RJA, Barth PG, Heymans HSA. Single peroxi-
somal enzyme deficiencies. In: Scriver CR, Beaudet AL,
Sly WS, Valle D, editors. The Molecular and Metabolic
Basis of Inherited Disease. New York: McGraw-Hill;
2001:3219–3256.
3. Demain LA, Urquhart JE, O’Sullivan J, et al. Expanding
the genotypic spectrum of Perrault syndrome. Clin Genet
Epub 2016 Mar 11. doi: .
4. Lieber DS, Hershman SG, Slate NG, et al. Next genera-
tion sequencing with copy number variant detection ex-
pands the phenotypic spectrum of HSD17B4-deficiency.
BMC Med Genet 2014;15:30.
5. Lines MA, Jobling R, Brady L, et al. Peroxisomal
D-bifunctional protein deficiency: three adults diag-
nosed by whole-exome sequencing. Neurology 2014;
82:963–968.
6. McMillan HJ, Worthylake T, Schwartzentruber J, et al.
Specific combination of compound heterozygous muta-
tions in 17beta-hydroxysteroid dehydrogenase type 4
(HSD17B4) defines a new subtype of D-bifunctional pro-
tein deficiency. Orphanet J Rare Dis 2012;7:90.
7. Pierce SB, Walsh T, Chisholm KM, et al. Mutations in the
DBP-deficiency protein HSD17B4 cause ovarian dysgen-
esis, hearing loss, and ataxia of Perrault Syndrome. Am J
Hum Genet 2010;87:282–288.
8. De Munter S, Verheijden S, Regal L, Baes M. Peroxisomal
disorders: a review on cerebellar pathologies. Brain Pathol
2015;25:663–678.
Neurology: Genetics 7
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
9. Wilson GR, Sim JC, McLean C, et al. Mutations in
RAB39B cause X-linked intellectual disability and early-
onset Parkinson disease with alpha-synuclein pathology.
Am J Hum Genet 2014;95:729–735.
10. 1000 Genomes Project Consortium, Auton A, Brooks LD,
et al. A global reference for human genetic variation.
Nature 2015;526:68–74.
11. Wilson GR, Sunley J, Smith KR, et al. Mutations in
SH3PXD2B cause Borrone dermato-cardio-skeletal syn-
drome. Eur J Hum Genet 2014;22:741–747.
12. Amor DJ, Delatycki MB, Gardner RJM, Storey E. New
variant of familial cerebellar ataxia with hypergonadotropic
hypogonadism and sensorineural deafness. Am J Med
Genet 2001;99:29–33.
13. Ferdinandusse S, Ylianttila MS, Gloerich J, et al. Muta-
tional spectrum of D-bifunctional protein deficiency and
structure-based genotype-phenotype analysis. Am J Hum
Genet 2006;78:112–124.
14. Crane DI. Revisiting the neuropathogenesis of Zellweger
syndrome. Neurochem Int 2014;69:1–8.
8 Neurology: Genetics
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/NXG.0000000000000114
2016;2; Neurol Genet 
David J. Amor, Ashley P.L. Marsh, Elsdon Storey, et al. 
protein deficiency
 cause juvenile peroxisomal D-bifunctionalHSD17B4Heterozygous mutations in 
This information is current as of October 18, 2016
Neurology. All rights reserved. Online ISSN: 2376-7839.
an open-access, online-only, continuous publication journal. Copyright © 2016 American Academy of 




including high resolution figures, can be found at:
References
 http://ng.neurology.org/content/2/6/e114.full.html##ref-list-1

















its entirety can be found online at:




Information about ordering reprints can be found online:
Neurology. All rights reserved. Online ISSN: 2376-7839.
an open-access, online-only, continuous publication journal. Copyright © 2016 American Academy of 
is an official journal of the American Academy of Neurology. Published since April 2015, it isNeurol Genet 
